Proteolytics Pty Ltd, based in Perth, is developing and commercialising OPAL-A, a proprietary botanical extract from paw paw fruit to treat hard-to-heal wounds for human and animal health. A 2nd-generation candidate, PL-001, combines OPAL-A with Proteolytics’ novel technology for enhancing and stabilising enzymatic activity, ProteoActiv™.

Proteolytics’ approach is to target hard-to-heal wounds:

  • where current debridement and wound-healing treatments are proving ineffective;
  • which are of greatest concern to the international medical community;
  • where enzymatic agents have shown activity in the clinical setting; and
  • where the ProteoActiv™ technology could improve efficacy by enhancing and stabilising enzymatic activity

To date, OPAL-A has been successfully investigated in hundreds of patients, with over 40 case reports fully documented, suffering from pressure ulcers, burns, venous ulcers, diabetic ulcers and skin disorders. OPAL-A has proven effective in treating all patients, some of whom achieved complete wound closure, which has been maintained for years.

In-vitro studies with the ProteoActiv™ technology have shown that it can enhance and stabilise the enzymatic activity of current standard-of-care enzymatic agents. Further studies are underway.

Proteolytics is working with international clinicians and research institutes, including the University of Florida and the Queen Mary University London. The Company’s products are addressing a global unmet medical need in wound care and a market size that was estimated to exceed US$24 billion in 2017¹.

¹Research and Markets, October 2018